Pages that link to "Q44059847"

The following pages link to Striatal neurochemical changes in transgenic models of Huntington's disease (Q44059847):

Displaying 37 items.

• Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease (Q24657764) (← links)
• Corticostriatal Dysfunction in Huntington's Disease: The Basics (Q26738379) (← links)
• Dopamine Receptors and Neurodegeneration (Q26783348) (← links)
• Modulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and Addiction diseases (Q26830654) (← links)
• Mouse models of polyglutamine diseases: review and data table. Part I (Q26853025) (← links)
• Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity (Q28239309) (← links)
• Decreased striatal RGS2 expression is neuroprotective in Huntington's disease (HD) and exemplifies a compensatory aspect of HD-induced gene regulation (Q28479035) (← links)
• Tetrabenazine is neuroprotective in Huntington's disease mice (Q33863426) (← links)
• Developmental alterations in motor coordination and medium spiny neuron markers in mice lacking pgc-1α (Q34391101) (← links)
• Striatal pre-enkephalin overexpression improves Huntington's disease symptoms in the R6/2 mouse model of Huntington's disease (Q34990529) (← links)
• In vivo Dopamine Efflux is Decreased in Striatum of both Fragment (R6/2) and Full-Length (YAC128) Transgenic Mouse Models of Huntington's Disease (Q35116551) (← links)
• Dopaminergic signaling and striatal neurodegeneration in Huntington's disease (Q35839434) (← links)
• Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease (Q36016647) (← links)
• The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies (Q36358871) (← links)
• Early-onset sleep defects in Drosophila models of Huntington's disease reflect alterations of PKA/CREB signaling (Q36581367) (← links)
• The corticostriatal pathway in Huntington's disease (Q36684263) (← links)
• Corticostriatal dysfunction underlies diminished striatal ascorbate release in the R6/2 mouse model of Huntington's disease (Q37349826) (← links)
• Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms (Q37731940) (← links)
• Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. (Q37930190) (← links)
• Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility (Q38121068) (← links)
• The role of dopamine in Huntington's disease (Q38223504) (← links)
• Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium (Q38603960) (← links)
• Hyperkinetic disorders and loss of synaptic downscaling (Q38847727) (← links)
• Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine Modulation (Q39041217) (← links)
• Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease (Q42525075) (← links)
• Type 1 cannabinoid receptor mapping with [18F]MK-9470 PET in the rat brain after quinolinic acid lesion: a comparison to dopamine receptors and glucose metabolism (Q42948746) (← links)
• Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. (Q44306949) (← links)
• Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF. (Q45125272) (← links)
• Striatal potassium channel dysfunction in Huntington's disease transgenic mice (Q45206241) (← links)
• Changes in Dopamine Signalling Do Not Underlie Aberrant Hippocampal Plasticity in a Mouse Model of Huntington's Disease. (Q45292629) (← links)
• Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. (Q45302139) (← links)
• Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease (Q45303900) (← links)
• Catecholamine exocytosis is diminished in R6/2 Huntington's disease model mice (Q45306447) (← links)
• Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease. (Q52676144) (← links)
• The adjustment of γ-aminobutyric acidA tonic subunits in Huntington's disease: from transcription to translation to synaptic levels into the neostriatum. (Q55427881) (← links)
• Cortical and Striatal Circuits in Huntington's Disease (Q89963713) (← links)
• Overview of Huntington's Disease Models: Neuropathological, Molecular, and Behavioral Differences (Q90439419) (← links)